Erlotinib plus ramucirumab (RAM) as first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation: phase 1B safety results and Phase 3 design of the ongoing Phase 1B/3 study RELAY

被引：0
|
作者：
Bischoff, H. [1 ]
Garon, E. B. [2 ]
Lee, P. [3 ]
He, S. [4 ]
Kropf-Sanchen, C. [5 ]
Kimmich, M. [6 ]
Nakagawa, K. [7 ]
Reck, M. [8 ]
机构：
[1] Univ Klinikum Heidelberg, Thoraxklin, Onkol Thoraxtumoren, Heidelberg, Germany
[2] Univ Calif Los Angeles, Med Ctr, Santa Monica, CA USA
[3] Eli Lilly & Co, Bridgewater, MA USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Univ Klinikum Ulm, Sekt Pneumol, Innere Med 2, Ulm, Germany
[6] Robert Bosch Krankenhaus, Klin Schillerhohe, Pneumol & Pneumol Onkol, Gerlingen, Germany
[7] Kinki Univ, Sch Med, Osaka, Japan
[8] German Ctr Lung Res DZL, LungenClin Grosshansdorf, ARCN, Grosshansdorf, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P593
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [41] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Dwan, Kerry
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Jain, Pooja
    Green, John A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (05):
  • [42] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Chaplin, Marty
    Green, John A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03):
  • [43] Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met plus non-small cell lung cancer by EGFR mutation status.
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan Wade
    Morgensztern, Daniel
    Heist, Rebecca Suk
    Vokes, Everett E.
    Spira, Alexander I.
    Angevin, Eric
    Su, Wu-Chou
    Hong, David S.
    Strickler, John H.
    Motwani, Monica
    Sun, Zhaowen
    Parikh, Apurvasena
    Noon, Elysa
    Wu, Jun
    Kelly, Karen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
    Besse, B.
    Barlesi, F.
    Demedts, I.
    Fuentes Pradera, J.
    Renault, A.
    Robinet, G.
    Frimodt-Moller, B.
    Gil, M.
    Vansteenkiste, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S76 - S76
  • [45] A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
    Besse, Benjamin
    Barlesi, Fabrice
    Demedts, Ingel
    Pradera, Jose Fuentes
    Robinet, Gilles
    Gazzah, Anas
    Soldatenkova, Victoria
    Frimodt-Moller, Bente
    Kim, Jong Seok
    Vansteenkiste, Johan
    [J]. LUNG CANCER, 2019, 137 : 136 - 143
  • [46] Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin plus /- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Griffith, Kent A.
    Zhen, David Bing
    Deming, Dustin A.
    Shroff, Rachna T.
    Hsieh, David
    Mahalingam, Devalingam
    Crysler, Oxana V.
    Alistar, Angela Tatiana
    Bajor, David L.
    Enzler, Thomas
    Zalupski, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] FIRST-LINE ERLOTINIB IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION: A MULTICENTRE ACADEMIC PHASE II STUDY IN BELGIUM
    De Greve, Jacques
    Van Meerbeeck, Jan P.
    Vansteenkiste, Johan
    Teugels, Erik
    Geers, Caroline
    Meert, Anne-Pascale
    Vuylsteke, Peter
    Focan, Christian
    Canon, Jean-Luc
    Humblet, Yves
    Berchem, Guy J.
    Colinet, Benoit
    Galdermans, Daniella
    Bosquee, Lionel
    Dooms, Christophe
    Decoster, Lore
    Vermeij, Joanna
    Dewaele, Alex
    Schallier, Denis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1270 - S1270
  • [48] Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
    Borad, Mitesh J.
    Bai, Li-Yuan
    Richards, Donald
    Mody, Kabir
    Hubbard, Joleen
    Rha, Sun Young
    Soong, John
    McCormick, Daniel
    Tse, Emmett
    O'Brien, Daniel
    Bayat, Ahmad
    Ahn, Daniel
    Davis, S. Lindsey
    Park, Joon Oh
    Oh, Do-Youn
    [J]. HEPATOLOGY, 2023, 77 (03) : 760 - 773
  • [49] TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Wolf, Juergen
    Litten, Jason B.
    Higashi, Linda A.
    Isaacson, Jeffrey D.
    Mok, Tony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut plus )
    Petruzelka, Lubos
    [J]. LUNG CANCER, 2012, 77 : S25 - S25
12345